Overview

• GSK posted Q1 2025 turnover of £7.52 billion and core profit of 44.9 pence per share, exceeding analyst expectations.
• Specialty medicines sales grew by 17%, driven by respiratory, immunology, and HIV treatments, while vaccine revenues fell 6%.
• The company reaffirmed its 2025 financial guidance, projecting turnover growth of 3-5% and core operating profit growth of 6-8%.
• GSK declared itself well positioned to manage potential US pharmaceutical tariffs, citing supply chain and productivity measures as mitigation strategies.
• A £2 billion share buyback program launched earlier this year has already repurchased £273 million in shares, reflecting GSK's commitment to shareholder returns.